VRTX up +2.15% percent Today $VRTX High is at 114.
Post# of 76
Posted On: 11/19/2014 10:54:40 AM
VRTX up +2.15% percent Today $VRTX High is at 114.50 and the Low 111.00 with current volume of 248,754.
Recent News posted below.
Vertex Pharmaceuticals Inc VRTX other info.
http://investorshangout.com/Vertex-Pharmaceut...RTX-55841/
VRTX Vertex Pharmaceuticals Inc Recent Headline News
Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF
PR Newswire - 1 hr 51 mins ago
The Cystic Fibrosis Foundation announced today that its nonprofit affiliate, Cystic Fibrosis Foundation Therapeutics, has sold its royalty rights for CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation sold the rights to Royalty Pharma for $3.3 billion.
VRTX: 115.12 (+4.08)
Earnings Look Back: Vertex Pharmaceuticals Is Down 2.4% Since Reporting Quarterly Results 2 Weeks Ago (VRTX)
Comtex SmarTrend(R) - Mon Nov 17, 4:06PM CST
When Vertex Pharmaceuticals (NASDAQ:VRTX) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report a loss of $0.44 on sales of $147.5 million. Vertex Pharmaceuticals actually reported a loss of $0.37 per share on sales of $179.0 million, beating EPS estimates by $0.07 and beating revenue estimates by $31.5 million. Shares of Vertex Pharmaceuticals have slipped from $114.07 to $111.34, representing a loss of 2.4%, since the company reported earnings 20 days ago.
VRTX: 115.12 (+4.08)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.72 (+0.09), HAS: 56.16 (+0.04), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), HAL: 47.83 (-0.71), M: 61.79 (+0.34), WMT: 84.48 (+0.69), SLB: 94.06 (-1.22), COG: 33.85 (+0.58), GILD: 101.55 (-2.16), EOG: 97.00 (-0.67), ALXN: 191.86 (-0.51), MRO: 32.08 (+0.02), CSCO: 26.31 (-0.28), BHI: 62.72 (-0.83)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 1.22% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 4:25PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $110.05 to a high of $114.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $111.85 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 115.12 (+4.08)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51), AMGN: 161.71 (-0.53), IBB: 294.30 (-0.95), REGN: 413.59 (+0.37), CELG: 106.36 (-0.42)
Vertex Pharmaceuticals Shares Up 21.7% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 12, 5:00PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 21.71% as of today's recent price of $116.68.
VRTX: 115.12 (+4.08)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ACHN: 13.13 (-0.18), DNDN: 0.13 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.82 (-0.23), REGN: 413.59 (+0.37)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), DNDN: 0.13 (-0.02), AZN: 74.38 (+0.40), TEVA: 57.38 (+0.15), ABBV: 65.82 (-0.23), GSK: 45.97 (-0.31), BMY: 58.67 (-0.03), NVS: 95.28 (-0.30)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.15 (-0.01), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), AFFX: 9.00 (-0.58)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 5.11% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 5.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)
Vertex Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 05, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 17.23% as of today's recent price of $112.39.
VRTX: 115.12 (+4.08)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 85.16 (-3.64), VRTX: 115.12 (+4.08), BMRN: 85.14 (-0.31), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.12 (+4.08), GERN: 3.15 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.81 (-0.24), AEGR: 20.78 (+0.29), SNY: 47.97 (-0.39), REGN: 413.59 (+0.37)
Vertex files marketing apps for CF combo
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:55AM CST
VRTX: 115.12 (+4.08)
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Business Wire - Wed Nov 05, 6:02AM CST
---Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation-
VRTX: 115.12 (+4.08)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.27 (-0.56), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), ABBV: 65.80 (-0.25)
Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Business Wire - Thu Oct 30, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.
VRTX: 115.12 (+4.08)
Recent News posted below.
Vertex Pharmaceuticals Inc VRTX other info.
http://investorshangout.com/Vertex-Pharmaceut...RTX-55841/
VRTX Vertex Pharmaceuticals Inc Recent Headline News
Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF
PR Newswire - 1 hr 51 mins ago
The Cystic Fibrosis Foundation announced today that its nonprofit affiliate, Cystic Fibrosis Foundation Therapeutics, has sold its royalty rights for CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation sold the rights to Royalty Pharma for $3.3 billion.
VRTX: 115.12 (+4.08)
Earnings Look Back: Vertex Pharmaceuticals Is Down 2.4% Since Reporting Quarterly Results 2 Weeks Ago (VRTX)
Comtex SmarTrend(R) - Mon Nov 17, 4:06PM CST
When Vertex Pharmaceuticals (NASDAQ:VRTX) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report a loss of $0.44 on sales of $147.5 million. Vertex Pharmaceuticals actually reported a loss of $0.37 per share on sales of $179.0 million, beating EPS estimates by $0.07 and beating revenue estimates by $31.5 million. Shares of Vertex Pharmaceuticals have slipped from $114.07 to $111.34, representing a loss of 2.4%, since the company reported earnings 20 days ago.
VRTX: 115.12 (+4.08)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.72 (+0.09), HAS: 56.16 (+0.04), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), HAL: 47.83 (-0.71), M: 61.79 (+0.34), WMT: 84.48 (+0.69), SLB: 94.06 (-1.22), COG: 33.85 (+0.58), GILD: 101.55 (-2.16), EOG: 97.00 (-0.67), ALXN: 191.86 (-0.51), MRO: 32.08 (+0.02), CSCO: 26.31 (-0.28), BHI: 62.72 (-0.83)
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 1.22% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 4:25PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $110.05 to a high of $114.23. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $111.85 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 115.12 (+4.08)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51), AMGN: 161.71 (-0.53), IBB: 294.30 (-0.95), REGN: 413.59 (+0.37), CELG: 106.36 (-0.42)
Vertex Pharmaceuticals Shares Up 21.7% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 12, 5:00PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 21.71% as of today's recent price of $116.68.
VRTX: 115.12 (+4.08)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), ACHN: 13.13 (-0.18), DNDN: 0.13 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.82 (-0.23), REGN: 413.59 (+0.37)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), DNDN: 0.13 (-0.02), AZN: 74.38 (+0.40), TEVA: 57.38 (+0.15), ABBV: 65.82 (-0.23), GSK: 45.97 (-0.31), BMY: 58.67 (-0.03), NVS: 95.28 (-0.30)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.15 (-0.01), BIIB: 304.05 (-1.51), VRTX: 115.12 (+4.08), AFFX: 9.00 (-0.58)
Look for Shares of Vertex Pharmaceuticals to Potentially Pullback after Yesterday's 5.11% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)
SmarTrend Watching for Potential Pullback in Shares of Vertex Pharmaceuticals After 5.11% Gain
Comtex SmarTrend(R) - Thu Nov 06, 4:21PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $111.85 to a high of $117.61. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $115.52 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.12 (+4.08)
Vertex Pharmaceuticals Shares Up 17.2% Since SmarTrend's Buy Recommendation (VRTX)
Comtex SmarTrend(R) - Wed Nov 05, 11:07AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 2 months, Vertex Pharmaceuticals has returned 17.23% as of today's recent price of $112.39.
VRTX: 115.12 (+4.08)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 85.16 (-3.64), VRTX: 115.12 (+4.08), BMRN: 85.14 (-0.31), GILD: 101.55 (-2.16), ALXN: 191.86 (-0.51)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.12 (+4.08), GERN: 3.15 (-0.02), AMGN: 161.71 (-0.53), ABBV: 65.81 (-0.24), AEGR: 20.78 (+0.29), SNY: 47.97 (-0.39), REGN: 413.59 (+0.37)
Vertex files marketing apps for CF combo
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:55AM CST
VRTX: 115.12 (+4.08)
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Business Wire - Wed Nov 05, 6:02AM CST
---Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation-
VRTX: 115.12 (+4.08)
5 Staggering Statistics About the Fastest Growing Drug in the World
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 01, 2:37PM CDT
Source: Flickr user Sergei Golyshev. In order for biotech companies to be successful they need to do two things very well: get drugs approved by the Food and Drug Administration and properly launch their approved drug. Even as recently as a...
JNJ: 108.27 (-0.56), VRTX: 115.12 (+4.08), GILD: 101.55 (-2.16), MRK: 59.38 (-0.51), ABBV: 65.80 (-0.25)
Vertex to Present at the Credit Suisse Healthcare Conference on November 11
Business Wire - Thu Oct 30, 3:02PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET.
VRTX: 115.12 (+4.08)
(0)
(0)